Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells

Immunopharmacology

Volumn 40, Issue 1, 1998, Pages 1-9

  Conry, Robert M ^a   Bantia, Shanta ^b   Turner, Heather S ^a   Barlow, Daunte L ^a   Allen, Karen O ^a   Lobuglio, Albert F ^a   Montgomery, John A ^b   Walsh, Gerald M ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

BCX 34; IL 2; Mixed lymphocyte reaction; OKT3; Purine nucleoside phosphorylase; T cell; Tetanus toxoid

Indexed keywords

INTERLEUKIN 2; OKT 3; PELDESINE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; TETANUS TOXOID;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; T LYMPHOCYTE;

CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GUANINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MUROMONAB-CD3; PURINE-NUCLEOSIDE PHOSPHORYLASE; T-LYMPHOCYTES; TETANUS TOXIN;

EID: 0031669919     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(98)00012-5     Document Type: Article

References (23)

1. Bantia S., Montgomery J.A., Johnson H.G., Walsh G.M. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology. 35:1996;53-63.
2. Bennett L.L. Jr., Allan P.W., Noker P.E., Rose L.M., Niwas S., Montgomery J.A., Erion M.D. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. J. Pharmacol. Exp. Ther. 266:1993;707-714.
3. Boehncke W.H., Gilbertsen R.B., Hemmer J., Sterry W. Evidence for a pathway independent from 2′-deoxyguanosine and reversible by IL-2 by which purine nucleoside phosphorylase inhibitors block T-cell proliferation. Scand. J. Immunol. 39:1994;327-332.
4. Catapano C.V., Dayton J.S., Mitchell B.S., Fernandes D.J. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol. Pharmacol. 47:1995;948-955.
5. Eriksson S., Thelander L., Kaerman M. Allosteric regulation of calf thymus ribonucleoside diphosphate reductase. Biochemistry. 18:1979;2946-2952.
6. Gilbertsen R.B., Scott M.E., Dong M.K., Kossarek L.M., Bennet M.K., Schrier D.J., Sircar J.C. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor. Agents Actions. 21:1987;272-274.
7. Gilbertsen R.B., Josyula U., Sircar J.C., Dong M.K., Wilburn D.J., Conroy M.C. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955. Biochem. Pharmacol. 44:1992;996-999.
8. Gilbertsen R.B., Dong M.K., Josyula U., Sircar J.C., Wilburn D.J., Conroy M.C. Activities of two 9-deazaguanine analogue inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955, in vitro and in vivo. Ann. New York Acad. Sci. 685:1993;248-251.
9. Greene et al., 1986.
10. Krensky A.M. T-lymphocyte-antigen interactions in transplant rejection. New Engl. J. Med. 322:1990;510-517.
11. Kumar V., Kono D.H., Urban J.L., Hood L. The T-cell receptor repertoire and autoimmune diseases. Annu. Rev. Immunol. 7:1989;657-682.
12. Madsen M., Johnson H.E. A methodological study of E-rosette formation using AET-treated sheep erythrocytes. J. Immunol. Methods. 27:1979;61-74.
13. Markert M.L. Purine nucleoside phosphorylase deficiency. Immuno-deficiency Rev. 3:1991;45-81.
14. Montgomery J.A., Niwas S., Rose J.D., Secrist J.A. III, Babu Y.S., Bugg C.E., Erion M.D., Guida W.C., Ealick S.E. Structure-based design of inhibitors of purine nucleoside phosphorylase: 9-(arylmethyl) derivatives of 9-deazaguanine. J. Med. Chem. 36:1993;55-69.
15. Montgomery J.A., Snyder H.W., Walsh D.A., Walsh G.M. BCX-34, purine nucleoside phosphorylase (PNP) inhibitor. Drugs Future. 18:1993;887-890.
16. Otterness, I.G., Bliven, M.L., 1989. The T-cell as a therapeutic target. In: Rainsford, K.D., Velo, G.P. (Eds.), New Developments in Antirheumatic Therapy, Inflammation and Drug Therapy Series, III, Kluwer Academic Publishers, pp. 276-304.
17. Scharenberg J.G.M., Rijkers G.T., Spaapen L.J.M., Toebes E.A.H., Rijksen G., Duran M., Staal G.E.J., Zegers B.J.M. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages. Int. J. Immunopharmacol. 10:1988;675-686.
18. Smith K.A. T-cell growth factor. Immunol. Rev. 51:1980;337-357.
19. Spaapen L.J.M., Rijkers G.T., Stall G.E.J., Rijksen G., Wadman S.K., Stoop J.W., Zegers B.J.M. The effect of deoxyguanosine on human lymphocyte function: I. Analysis of the interference with lymphocyte proliferation in vitro. J. Immunol. 132:1984;2311-2317.
20. Stoeckler J.D., Ealick S.E., Bugg C.E., Parks R.E. Jr. Design of purine nucleoside phosphorylase inhibitors. Fed. Proc. 45:1986;2773-2778.
21. Valentine M.A., Tsoukas C.D., Rhodes G., Vaughn J.H., Carson D.A. Phytohemagglutinin binds to the 20-kDa molecule of the T3 complex. Eur. J. Immunol. 15:1985;851-854.
22. Walsh G.M., Reddy N.S., Bantia S., Babu Y.S., Montgomery J.A. Development of inhibitors of purine nucleoside phosphorylase. Hematol. Rev. 8:1994;87-97.
23. Wilburn D.J., Dong M.K., Gilbertsen R.B. PD 141955 and CI-972: 9 deazaguanine analog purine nucleoside phosphorylase inhibitors: I. Suppression of the human mixed lymphocyte reaction (MLR). Agents Actions. 39:1993;C96-C98. (special conference issue).